{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05838066","nct_id":"NCT05838066","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05838066. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects will receive an intravenous (IV) infusion of KN026 plus HB1801. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurrs first.","label":"KN026+HB1801","type":"EXPERIMENTAL"},{"description":"On Day 1 of each 21-day cycle, patients will receive an intravenous (IV) infusion of Pertuzumab 840 mg loading dose followed by 420 mg per cycle, IV, D1, Q3W, in combination with trastuzumab 8 mg/kg loading dose followed by 6 mg/kg per cycle, IV, D1, Q3W and docetaxel 75 mg/m\\^2. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurred first.","label":"Trastuzumab + Pertuzumab + Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer"],"enrollment":{"count":880,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Recombinant Humanized Bispecific antibody against HER2，KN026","otherNames":[],"type":"DRUG"},{"name":"HB1801","otherNames":[],"type":"DRUG"},{"name":"Pertuzumab","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2025-05-30","lead_sponsor":"Shanghai JMT-Bio Inc.","official_title":"A Randomized, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).","timeFrame":"Up to approximately 4 years"}],"references":[],"start_date":{"date":"2023-07-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","url":"https://clinicaltrials.gov/study/NCT05838066"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05838066"}